Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.66 |
| ▸ | PRKDC | P78527 | 10/20 | 0.66 |
| ▸ | ATM | Q13315 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336653 | 0.90 | ATR (0.53) | ATRPRKDCATMCYP3A4ATRIP | |
| SCHEMBL2484432 | 0.87 | ATR (0.67) | ATRCYP3A4 | |
| SCHEMBL23703155 | 0.87 | ATR (0.64) | ATRPRKDCATMATRIP | |
| SCHEMBL23419962 | 0.86 | ATR (0.69) | ATRPRKDC | |
| SCHEMBL23389767 | 0.86 | ATR (0.57) | ATRPRKDCATM | |
| SCHEMBL23732912 | 0.85 | ATR (0.63) | ATRPRKDCATMATRIP | |
| SCHEMBL4928363 | 0.85 | ATR (0.63) | ATRPRKDCATMATRIP | |
| SCHEMBL3461817 | 0.85 | IKBKB (0.49) | ATRPRKDCATM | |
| SCHEMBL23389810 | 0.85 | ATR (0.67) | ATRPRKDCATM | |
| SCHEMBL14525246 | 0.84 | ATR (0.65) | ATRPRKDCATMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195490-B2 | STRAD-binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-14 | — | — | US | disclosed |
| CN-115916966-A | STRAD binding agents and uses thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| EP-4097223-A1 | STRAD-BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4059932-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-3354650-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11179394-B2 | Method for treating cancer using a combination of Chk1 and ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-11-23 | — | — | US | disclosed |
| WO-2021155004-A1 | STRAD-BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155004-A1 | STRAD-BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | WO | disclosed |
| US-10961232-B2 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-03-30 | — | — | US | disclosed |
| US-20040072847-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1368345-A1 | ALKOXYCARBONYLAMINO HETEROARYL CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003093297-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-1347982-A2 | SPIRO ISOBENZOFURAN-1,4'-PIPERIDIN]-3-ONES AND 3H-SPIROISOBENZOFURAN-1,4'-PIPERIDINES | Neurogen Corporation (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6569860-B2 | Alkoxycarbonylamino-heteroaryl carboxylic acid derivatives useful for treating the disorders of the urinary tract, pain, inflammation, respiratory states, edema formation, hypotensive vascular diseases, pain and allergies | ROćHE PALO ALTO LLC | 2003-05-27 | — | — | US | disclosed |
| US-6566367-B2 | For therapy of eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension in humans, domesticated companion animals and livestock animals | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| US-20030036652-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NEUROGEN CORPORATION | 2003-02-20 | — | — | US | disclosed |
| US-20020169171-A1 | Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as IP antagonists | SYNTEX (USA) LLC | 2002-11-14 | — | — | US | disclosed |
| WO-2002070514-A1 | ALKOXYCARBONYLAMINO HETEROARYL CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002048152-A2 | SPIRO[ISOBENZOFURAN-1,4'-PIPERIDIN]-3-ONES AND 3H-SPIROISOBENZOFURAN-1,4'-PIPERIDINES | NEUROGEN CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072847-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, NPY1R | ATR 4634/4885PRKDC 4671/4885ATM 4428/4885 |
| US-10961232-B2 | Substituted pyrazines as ATR kinase inhibitors | ATR, MAP3K5, CHEK1 | ATR 1/4885PRKDC 29/4885ATM 41/4885 |
| US-11179394-B2 | Method for treating cancer using a combination of Chk1 and ATR inhibitors | CHEK1, CHEK2, ATR | ATR 3/4885PRKDC 73/4885ATM 7/4885 |
| US-20020169171-A1 | Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as IP antagonists | GPBAR1, GCGR, CNR1 | ATR 4042/4885PRKDC 4574/4885ATM 4691/4885 |
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885PRKDC 23/4885ATM 39/4885 |
| US-20030036652-A1 | Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines | NPY5R, NPY4R, NPY1R | ATR 4634/4885PRKDC 4671/4885ATM 4428/4885 |
| US-12195490-B2 | STRAD-binding agents and uses thereof | STRAP, STRA6, PLAUR | ATR 3836/4885PRKDC 467/4885ATM 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.